SOUTH SAN FRANCISCO, Calif.,April 13, 2026(GLOBE NEWSWIRE) --Allogene Therapeutics, Inc.(Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions,$175 millionof shares of its common stock. All of the shares are being offered by Allogene. In addition, Allogene intends to grant the underwriters for the offering a 30-day option to purchase up to an additional$26.25 millionof the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures.
Goldman Sachs & Co. LLC, Jefferies andTD Cowenare acting as the joint book-running managers for the offering.TPG Capital BD, LLCis acting as co-manager for the offering.
The shares of common stock described above are being offered by Allogene pursuant to a shelf registration statement filed by Allogene with the Securities and Exchange Commission (SEC) that was declared effective onApril 25, 2024. A preliminary prospectus supplement related to the offering will be filed with theSECand will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained fromGoldman Sachs & Co. LLC, Attention: Prospectus Department,200 West Street,New York, NY10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or fromJefferies LLC, Attention:Equity Syndicate Prospectus Department,520 Madison Avenue,New York, New York10022, or by telephone at (877) 821-7388, or by emailing prospectus_department@jefferies.com; or fromTD Securities (USA) LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue,Edgewood, NY11717, or by email at TDManualrequest@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.